Bile acids in physiology, pathology and pharmacology

Current Drug Metabolism

Volumn 17, Issue 1, 2016, Pages 4-29

  Marin, Jose J G ^a,c   Macias, Rocio I R ^a,c   Briz, Oscar ^a,c   Banales, Jesus M ^b,c   Monte, Maria J ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biliary tree; Cholangiocyte; Cholesterol; Digestion; Hepatocyte; Intestine; Lipid; Liver; Metabolism; Secretion; Steroid; Transport

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; MEMBRANE RECEPTOR; PREGNANE X RECEPTOR; STEROL; VITAMIN D RECEPTOR; ALISOL B 23-ACETATE; CHOLEST 4 EN 3 ONE;

ABSORPTION; ADIPOSE TISSUE; AMIDATION; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT DISEASE; BIOAVAILABILITY; BIOTRANSFORMATION; CELL MEMBRANE; CHOLESTASIS; DYNAMICS; ENERGY; ENHANCER REGION; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL MOTILITY; GLUCOSE METABOLISM; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE; KIDNEY; LIVER; LIVER DISEASE; LUNG; MACROMOLECULE; MOLECULAR INTERACTION; PARACRINE SIGNALING; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; PLACENTA; REVIEW; ANIMAL; BILE; CHEMISTRY; DRUG EFFECTS; HUMAN; LIVER CELL; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BILE; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTENONES; HEPATOCYTES; HUMANS; INTESTINES; LIVER;

EID: 84954051044     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666151103115454     Document Type: Review

References (375)

1. Hofmann, A. F.; Hagey, L. R. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J. Lipid Res., 2014, 55(8), 1553-1595.
2. Marin, J. J. How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. World J. Gastroenterol., 2008, 14(37), 5617-5619.
3. Monte, M. J.; Marin, J. J.; Antelo, A.; Vazquez-Tato, J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol., 2009, 15(7), 804-816.
4. Hofmann, A. F.; Sjovall, J.; Kurz, G.; Radominska, A.; Schteingart, C. D.; Tint, G. S.; Vlahcevic, Z. R.; Setchell, K. D. A proposed nomenclature for bile acids. J. Lipid Res., 1992, 33(4), 599-604.
5. 2+ ions. J. Lipid Res., 1992, 33(5), 617-626.
6. Coello, A.; Meijide, F.; Nunez, E. R.; Tato, J. V. Aggregation behavior of bile salts in aqueous solution. J. Pharm. Sci., 1996, 85(1), 9-15.
7. Coleman, R. Bile salts and biliary lipids. Biochem. Soc. Trans., 1987, 15(Suppl), 68S-80S.
8. Koop, I.; Schindler, M.; Bosshammer, A.; Scheibner, J.; Stange, E.; Koop, H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut, 1996, 39(5), 661-667.
9. Begley, M.; Gahan, C. G.; Hill, C. The interaction between bacteria and bile. FEMS Microbiol. Rev., 2005, 29(4), 625-651.
10. Axelson, M.; Ellis, E.; Mork, B.; Garmark, K.; Abrahamsson, A.; Bjorkhem, I.; Ericzon, B. G.; Einarsson, C. Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid. Hepatology, 2000, 31(6), 1305-1312.
11. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem., 2003, 72, 137-174.
12. Chiang, J. Y. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol., 2004, 40(3), 539-551.
13. Norlin, M.; Wikvall, K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med., 2007, 7(2), 199-218.
14. Zhang, M.; Chiang, J. Y. Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem., 2001, 276(45), 41690-41699.
15. Chen, M.; Penning, T. M. 5[3-Reduced steroids and human 8 (4)-3-ketosteroid 5β-reductase (AKR1D1). Steroids, 2014, 83, 17-26.
16. Solaas, K.; Ulvestad, A.; Soreide, O.; Kase, B. F. Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts. J. Lipid Res. 2000, 41(7), 1154-62.
17. Pellicoro, A.; Van Den Heuvel, F. A.; Geuken, M.; Moshage, H.; Jansen, P. L.; Faber, K. N. Human and rat bile acid-CoA: amino acid N-acyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport. Hepatology, 2007, 45(2), 340-348.
18. Mihalik, S. J.; Steinberg, S. J.; Pei, Z.; Park, J.; Kim, D. G.; Heinzer, A. K.; Dacremont, G.; Wanders, R. J.; Cuebas, D. A.; Smith, K. D.; Watkins, P. A. Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling. J. Biol. Chem., 2002, 277(27), 24771-24779.
19. 3H. J. Clin. Invest. 1972, 51(1), 112-7.
20. Axelson, M.; Sjovall, J. Potential bile acid precursors in plasma-possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. J. Steroid Biochem., 1990, 36(6), 631-640.
21. Stravitz, R. T.; Vlahcevic, Z. R.; Russell, T. L.; Heizer, M. L.; Avadhani, N. G.; Hylemon, P. B. Regulation of sterol 27-hydroxylase and an alternative pathway of bile acid biosynthesis in primary cultures of rat hepatocytes. J. Steroid Biochem. Mol. Biol, 1996, 57(5-6), 337-347.
22. Lund, E. G.; Guileyardo, J. M.; Russell, D. W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(13), 7238-7243.
23. Dooley, T. P.; Haldeman-Cahill, R.; Joiner, J.; Wilborn, T. W. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem. Biophys. Res. Commun., 2000, 277(1), 236-245.
24. King, CD.; Rios, G. R.; Green, M. D.; Tephly, T. R. UDP-glucuronosyltransferases. Curr. Drug Metab., 2000, 1(2), 143-161.
25. Barbier, O.; Trottier, J.; Kaeding, J.; Caron, P.; Verreault, M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell Biochem., 2009, 326(1-2), 3-8.
26. Alme, B.; Sjovall, J. Analysis of bile acid glucuronides in urine. Identification of 3α, 6α, 12α-trihydroxy-5P-cholanoic acid. J. Steroid Biochem., 1980, 13(8), 907-916.
27. Heuman, D. M.; Hylemon, P. B.; Vlahcevic, Z. R. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J. Lipid Res., 1989, 30(8), 1161-1171.
28. Pandak, W. M.; Vlahcevic, Z. R.; Heuman, D. M.; Redford, K. S.; Chiang, J. Y.; Hylemon, P. B. Effects of different bile salts on steady-state mRNA levels and transcriptional activity of cholesterol 7α-hydroxylase. Hepatology, 1994, 19(4), 941-947.
29. Stroup, D.; Crestani, M.; Chiang, J. Y. Identification of a bile acid response element in the cholesterol 7α-hydroxylase gene CYP7A. Am. J. Physiol. Gastrointest. Liver Physiol, 1997, 273(2), G508-G517.
30. Yang, Y.; Zhang, M.; Eggertsen, G.; Chiang, J. Y. On the mechanism of bile acid inhibition of rat sterol 12α-hydroxylase gene (CYP8B1) transcription: roles of α-fetoprotein transcription factor and hepatocyte nuclear factor 4α. Biochim. Biophys. Acta, 2002, 1583(1), 63-73.
31. Goodwin, B.; Jones, S. A.; Price, R. R.; Watson, M. A.; McKee, D. D.; Moore, L. B.; Galardi, C; Wilson, J. G.; Lewis, M. C.; Roth, M. E.; Maloney, P. R.; Willson, T. M.; Kliewer, S. A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell, 2000, 6(3), 517-526.
32. Kir, S.; Zhang, Y.; Gerard, R. D.; Kliewer, S. A.; Mangelsdorf, D. J. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7α1 In vivo. J. Biol. Chem., 2012, 287(49), 41334-41341.
33. Holt, J. A.; Luo, G.; Billin, A. N.; Bisi, J.; McNeill, Y. Y.; Kozarsky, K. F.; Donahee, M.; Wang, D. Y.; Mansfield, T. A.; Kliewer, S. A.; Goodwin, B.; Jones, S. A. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev, 2003, 17(13), 1581-1591.
34. Inagaki, T.; Choi, M.; Moschetta, A.; Peng, L.; Cummins, C. L.; McDonald, J. G.; Luo, G.; Jones, S. A.; Goodwin, B.; Richardson, J. A.; Gerard, R. D.; Repa, J. J.; Mangelsdorf, D. J.; Kliewer, S. A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab., 2005, 2(4), 217-225.
35. Kong, B.; Wang, L.; Chiang, J. Y.; Zhang, Y.; Klaassen, CD.; Guo, G. L. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology, 2012, 56(3), 1034-1043.
36. Li, S.; Hsu, D. D.; Li, B.; Luo, X.; Alderson, N.; Qiao, L.; Ma, L.; Zhu, H. H.; He, Z.; Suino-Powell, K.; Ji, K.; Li, J.; Shao, J.; Xu, H. E.; Li, T.; Feng, G. S. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab., 2014, 20(2), 320-332.
37. Katafuchi, T.; Esterhazy, D.; Lemoff, A.; Ding, X.; Sondhi, V.; Kliewer, S. A.; Mirzaei, H.; Mangelsdorf, D. J. Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab., 2015, 21(6), 898-904.
38. Rodriguez-Ortigosa, CM.; Celay, J.; Olivas, I.; Juanarena, N.; Arcelus, S.; Uriarte, I.; Marin, J. J.; Avila, M. A.; Medina, J. F.; Prieto, J. A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver. Gastroenterology, 2014, 147(5), 1084-1093.
39. De Aguiar Vallim, T. Q.; Tarling, E. J.; Ahn, H.; Hagey, L. R.; Romanoski, C. E.; Lee, R. G.; Graham, M. J.; Motohashi, H.; Yamamoto, M.; Edwards, P. A. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab., 2015, 21(2), 298-310.
40. Chiang, J. Y.; Kimmel, R.; Stroup, D. Regulation of cholesterol 7α-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRa). Gene, 2001, 262(1-2), 257-265.
41. Goodwin, B.; Watson, M. A.; Kim, H.; Miao, J.; Kemper, J. K.; Kliewer, S. A. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-α. Mol. Endocrinol, 2003, 17(3), 386-394.
42. Twisk, J.; Hoekman, M. F.; Lehmann, E. M.; Meijer, P.; Mager, W. H.; Princen, H. M. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology, 1995, 21(2), 501-10.
43. Li, T.; Kong, X.; Owsley, E.; Ellis, E.; Strom, S.; Chiang, J. Y. Insulin regulation of cholesterol 7α-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. J. Biol Chem., 2006, 281(39), 28745-28754.
44. Li, T.; Chanda, D.; Zhang, Y.; Choi, H. S.; Chiang, J. Y. Glucose stimulates cholesterol 7α-hydroxylase gene transcription in human hepatocytes. J. Lipid Res., 2010, 51(4), 832-842.
45. Ness, G. C; Lopez, D. Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7α-hydroxylase by thyroid hormone. Arch. Biochem. Biophys., 1995, 323(2), 404-408.
46. Sauter, G.; Weiss, M.; Hoermann, R. Cholesterol 7α-hydroxylase activity in hypothyroidism and hyperthyroidism in humans. Horm. Metab. Res., 1997, 29(4), 176-179.
47. Lammel Lindemann, J. A.; Angajala, A.; Engler, D. A.; Webb, P.; Ayers, S. D. Thyroid hormone induction of human cholesterol 7α-hydroxylase (Cyp7a1) In vitro. Mol. Cell Endocrinol, 2014, 388(1-2), 32-40.
48. Song, Y.; Xu, C; Shao, S.; Liu, J.; Xing, W.; Xu, J.; Qin, C; Li, C; Hu, B.; Yi, S.; Xia, X.; Zhang, H.; Zhang, X.; Wang, T.; Pan, W.; Yu, C; Wang, Q.; Lin, X.; Wang, L.; Gao, L.; Zhao, J. Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis. J. Hepatol, 2015, 62(5), 1171-1179.
49. Miao, J.; Fang, S.; Bae, Y.; Kemper, J. K. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1α. J. Biol. Chem., 2006, 281(21), 14537-14546.
50. Li, T.; Chiang, J. Y. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol, 2005, 288(1), G74-G84.
51. Ridlon, J. M.; Kang, D. J.; Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res., 2006, 47(2), 241-259.
52. Batta, A. K.; Salen, G.; Arora, R.; Shefer, S.; Batta, M.; Person, A. Side chain conjugation prevents bacterial 7-dehydroxylation of bile acids. J. Biol. Chem., 1990, 265(19), 10925-10928.
53. Hofmann, A. F.; Hagey, L. R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci., 2008, 65(16), 2461-2483.
54. +/bile acid cotransporter. J. Clin. Invest., 1994, 93(3), 1326-1331.
55. Yan, H.; Zhong, G.; Xu, G.; He, W.; Jing, Z.; Gao, Z.; Huang, Y.; Qi, Y.; Peng, B.; Wang, H.; Fu, L.; Song, M.; Chen, P.; Gao, W.; Ren, B.; Sun, Y.; Cai, T.; Feng, X.; Sui, J.; Li, W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 2012, 1, e00049.
56. Yan, H.; Peng, B.; Liu, Y.; Xu, G.; He, W.; Ren, B.; Jing, Z.; Sui, J.; Li, W. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J. Virol, 2014, 88(6), 3273-3284.
57. Oehler, N.; Volz, T.; Bhadra, O. D.; Kah, J.; Allweiss, L.; Giersch, K.; Bierwolf, J.; Riecken, K.; Pollok, J. M.; Lohse, A. W.; Fehse, B.; Petersen, J.; Urban, S.; Lutgehetmann, M.; Heeren, J.; Dandri, M. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology, 2014, 60(5), 1483-1493.
58. Romero, M. R.; Monte, M. J.; Marin, J. J. Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP. Ann. Hepatol, 2015, 14(1), 143-144.
59. +/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology, 1996, 110(1), 199-209.
60. Aguilar-Olivos, N. E.; Carrillo-Cordova, D.; Oria-Hernandez, J.; Sanchez-Valle, V.; Ponciano-Rodriguez, G.; Ramirez-Jaramillo, M.; Chable-Montero, F.; Chavez-Tapia, N. C; Uribe, M.; Mendez-Sanchez, N. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Ann. Hepatol, 2015, 14(4), 487-493.
61. Craddock, A. L.; Love, M. W.; Daniel, R. W.; Kirby, L. C; Walters, H. C; Wong, M. H.; Dawson, P. A. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am. J. Physiol. Gastrointest. Liver Physiol, 1998, 274(1), G157-G169.
62. Splinter, P. L.; Lazaridis, K. N.; Dawson, P. A.; LaRusso, N. F. Cloning and expression of SLC10A4, a putative organic anion transport protein. World J. Gastroenterol, 2006, 12(42), 6797-6805.
63. Geyer, J.; Doring, B.; Meerkamp, K.; Ugele, B.; Bakhiya, N.; Fernandes, C. F.; Godoy, J. R.; Glatt, H.; Petzinger, E. Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J. Biol. Chem., 2007, 282(27), 19728-19741.
64. Fietz, D.; Bakhaus, K.; Wapelhorst, B.; Grosser, G.; Gunther, S.; Alber, J.; Doring, B.; Kliesch, S.; Weidner, W.; Galuska, C. E.; Hartmann, M. F.; Wudy, S. A.; Bergmann, M.; Geyer, J. Membrane transporters for sulfated steroids in the human testis-cellular localization, expression pattern and functional analysis. PLoS One, 2013, 8(5), e62638.
65. Abe, T.; Kanemitu, Y.; Nakasone, M.; Kawahata, I.; Yamakuni, T.; Nakajima, A.; Suzuki, N.; Nishikawa, M.; Hishinuma, T.; Tomioka, Y. SLC10A4 is a protease-activated transporter that transports bile acids. J. Biochem., 2013, 154(1), 93-101.
66. Schmidt, S.; Moncada, M.; Burger, S.; Geyer, J. Expression, sorting and transport studies for the orphan carrier SLC10A4 in neuronal and non-neuronal cell lines and in Xenopus laevis oocytes. BMC Neurosci., 2015, 16(1), 35.
67. Kullak-Ublick, G. A.; Ismair, M. G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P. J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 2001, 120(2), 525-533.
68. Briz, O.; Romero, M. R.; Martinez-Becerra, P.; Macias, R. I.; Perez, M. J.; Jimenez, F.; San Martin, F. G.; Marin, J. J. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J. Biol. Chem., 2006, 281(41), 30326-30335.
69. Mahagita, C.; Grassl, S. M.; Piyachaturawat, P.; Ballatori, N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293(1), G271-8.
70. Martinez-Becerra, P.; Briz, O.; Romero, M. R.; Macias, R. I.; Perez, M. J.; Sancho-Mateo, C.; Lostao, M. P.; Fernandez-Abalos, J. M.; Marin, J. J. Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol. Pharmacol., 2011, 79(3), 596-607.
71. Gerloff, T.; Stieger, B.; Hagenbuch, B.; Madon, J.; Landmann, L.; Roth, J.; Hofmann, A. F.; Meier, P. J. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem., 1998, 273(16), 10046-10050.
72. Van Mil, S. W.; Van Der Woerd, W. L.; Van Der Brugge, G.; Sturm, E.; Jansen, P. L.; Bull, L. N.; Van Den Berg, I. E.; Berger, R.; Houwen, R. H.; Klomp, L. W. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology, 2004, 127(2), 379-384.
73. Strautnieks, S. S.; Bull, L. N.; Knisely, A. S.; Kocoshis, S. A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M. S.; Kagalwalla, A. F.; Nemeth, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N. B.; Gardiner, R. M.; Thompson, R. J. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet., 1998, 20(3), 233-238.
74. Jansen, P. L.; Strautnieks, S. S.; Jacquemin, E.; Hadchouel, M.; Sokal, E. M.; Hooiveld, G. J.; Koning, J. H.; De Jager-Krikken, A.; Kuipers, F.; Stellaard, F.; Bijleveld, C. M.; Gouw, A.; Van Goor, H.; Thompson, R. J.; Muller, M. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology, 1999, 117(6), 1370-1379.
75. Marin, J. J.; Houwen, R. H. Treatment of paediatric cholestasis due to canalicular transport defects: yet another step forward. Gut, 2015, 64(1), 6-8.
76. Akita, H.; Suzuki, H.; Ito, K.; Kinoshita, S.; Sato, N.; Takikawa, H.; Sugiyama, Y. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta, 2001, 1511(1), 7-16.
77. Blazquez, A. G.; Briz, O.; Romero, M. R.; Rosales, R.; Monte, M. J.; Vaquero, J.; Macias, R. I.; Cassio, D.; Marin, J. J. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol. Pharmacol., 2012, 81(2), 273-283.
78. Soroka, C. J.; Lee, J. M.; Azzaroli, F.; Boyer, J. L. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology, 2001, 33(4), 783-791.
79. Geier, A.; Wagner, M.; Dietrich, C. G.; Trauner, M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta, 2007, 1773(3), 283-308.
80. Rius, M.; Hummel-Eisenbeiss, J.; Hofmann, A. F.; Keppler, D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(4), G640-G649.
81. Hirohashi, T.; Suzuki, H.; Takikawa, H.; Sugiyama, Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem., 2000, 275(4), 2905-2910.
82. Zelcer, N.; Reid, G.; Wielinga, P.; Kuil, A.; Van Der Heijden, I.; Schuetz, J. D.; Borst, P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J., 2003, 371(2), 361-7.
83. Stark, M.; Rothem, L.; Jansen, G.; Scheffer, G. L.; Goldman, I. D.; Assaraf, Y. G. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol., 2003, 64(2), 220-7.
84. Jimenez, F.; Monte, M. J.; El-Mir, M. Y.; Pascual, M. J.; Marin, JJ. Chronic renal failure-induced changes in serum and urine bile acid profiles. Dig. Dis. Sci., 2002, 47(11), 2398-406.
85. Dawson, P. A.; Hubbert, M.; Haywood, J.; Craddock, A. L.; Zerangue, N.; Christian, W. V.; Ballatori, N. The heteromeric organic solute transportera-P, Osta-Ostp, is an ileal basolateral bile acid transporter. J. Biol. Chem., 2005, 280(8), 6960-6968.
86. Fernandez-Barrena, M. G.; Monte, M. J.; Latasa, M. U.; Uriarte, I.; Vicente, E.; Chang, H. C.; Rodriguez-Ortigosa, CM.; Elferink, R. O.; Berasain, C; Marin, JJ.; Prieto, J.; Avila, M. A. Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. J. Hepatol, 2012, 56(2), 367-373.
87. Martinez-Augustin, O.; Sanchez De Medina, F. Intestinal bile acid physiology and pathophysiology. World J. Gastroenterol, 2008, 14(37), 5630-5640.
88. Gass, J.; Vora, H.; Hofmann, A. F.; Gray, G. M.; Khosla, C. Enhancement of dietary protein digestion by conjugated bile acids. Gastroenterology, 2007, 133(1), 16-23.
89. Hofmann, A. F.; Eckmann, L. How bile acids confer gut mucosal protection against bacteria. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(12), 4333-4334.
90. Mekhjian, H. S.; Phillips, S. F.; Hofmann, A. F. Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig. Dis. Sci., 1979, 24(7), 545-550.
91. Hofmann, A. F.; Poley, J. R. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology, 1972, 62(5), 918-934.
92. Hofmann, A. F.; Poley, J. R. Cholestyramine treatment of diarrhea associated with ileal resection. N. Engl. J. Med., 1969, 281(8), 397-402.
93. Wong, N. N. Colesevelam: a new bile acid sequestrant. Heart. Dis., 2001, 3(1), 63-70.
94. Acosta, A.; Camilleri, M. Elobixibat and its potential role in chronic idiopathic constipation. Therap. Adv. Gastroenterol, 2014, 7(4), 167-175.
95. Marin, J. J.; Barbero, E. R.; Herrera, M. C.; Tabernero, A.; Monte, M. J. Bile acid-induced modifications in DNA synthesis by the regenerating perfused rat liver. Hepatology, 1993, 18(5), 1182-92.
96. Barbero, E. R.; Herrera, M. C.; Monte, M. J.; Serrano, M. A.; Marin, JJ. Role of amidation in bile acid effect on DNA synthesis by regenerating mouse liver. Am. J. Physiol. Gastrointest. Liver Physiol, 1995, 268(6), G1051-G1059.
97. Lozano, E.; Sanchez-Vicente, L.; Monte, M. J.; Herraez, E.; Briz, O.; Banales, J. M.; Marin, J. J.; Macias, R. I. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol. Cancer. Res., 2014, 12(1), 91-100.
98. Martinez-Diez, M. C.; Serrano, M. A.; Monte, M. J.; Marin, JJ. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochim. Biophys. Acta, 2000, 1500(2), 153-160.
99. Uriarte, I.; Fernandez-Barrena, M. G.; Monte, M. J.; Latasa, M. U.; Chang, H. C.; Carotti, S.; Vespasiani-Gentilucci, U.; Morini, S.; Vicente, E.; Concepcion, A. R.; Medina, J. F.; Marin, J. J.; Berasain, C; Prieto, J.; Avila, M. A. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut, 2013, 62(6), 899-910.
100. Vergnes, L.; Lee, J. M.; Chin, R. G.; Auwerx, J.; Reue, K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab., 2013, 17(6), 916-928.
101. Reue, K.; Lee, J. M.; Vergnes, L. Diet1 is a regulator of fibroblast growth factor 15/19-dependent bile Acid synthesis. Dig. Dis., 2015, 33(3), 307-13.
102. Tabibian, J. H.; Masyuk, A. I.; Masyuk, T. V.; O'Hara, S. P.; LaRusso, N. F. Physiology of cholangiocytes. Compr. Physiol., 2013, 3(1), 541-565.
103. Banales, J. M.; Prieto, J.; Medina, J. F. Cholangiocyte anion exchange and biliary bicarbonate excretion. World J. Gastroenterol. 2006, 12(22), 3496-3511.
104. Rodriguez-Ortigosa, C. M.; Banales, J. M.; Olivas, I.; Uriarte, I.; Marin, J. J.; Corrales, F. J.; Medina, J. F.; Prieto, J. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology, 2010, 52(2), 667-77.
105. Beuers, U.; Trauner, M.; Jansen, P.; Poupon, R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J. Hepatol., 2015, 62(1S), S25-S37.
106. Schaap, F. G.; Trauner, M.; Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol., 2014, 11(1), 55-67.
107. Hohenester, S.; Wenniger, L. M.; Paulusma, C. C.; Van Vliet, S. J.; Jefferson, D. M.; Elferink, R. P.; Beuers, U. A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology, 2012, 55(1), 173-183.
108. Banales, J. M.; Arenas, F.; Rodriguez-Ortigosa, C. M.; Saez, E.; Uriarte, I.; Doctor, R. B.; Prieto, J.; Medina, J. F. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology, 2006, 43(2), 266-275.
109. - exchange. Hepatology, 2010, 51(3), 891-902.
110. Arenas, F.; Hervias, I.; Uriz, M.; Joplin, R.; Prieto, J.; Medina, J. F. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J. Clin. Invest., 2008, 118(2), 695-709.
111. 2+ and cAMP signaling. Gastroenterology, 2006, 131(3), 911-920.
112. Gradilone, S. A.; Masyuk, A. I.; Splinter, P. L.; Banales, J. M.; Huang, B. Q.; Tietz, P. S.; Masyuk, T. V.; Larusso, N. F. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(48), 19138-19143.
113. Masyuk, A. I.; Gradilone, S. A.; Banales, J. M.; Huang, B. Q.; Masyuk, T. V.; Lee, S. O.; Splinter, P. L.; Stroope, A. J.; Larusso, N. F. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 295(4), G725-G734.
114. Masyuk, A. I.; Huang, B. Q.; Radtke, B. N.; Gajdos, G. B.; Splinter, P. L.; Masyuk, T. V.; Gradilone, S. A.; La Russo, N. F. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am. J. Physiol. Gastrointest. Liver Physiol., 2013, 304(11), G1013-G1024.
115. Masyuk, A. I.; Huang, B. Q.; Ward, C. J.; Gradilone, S. A.; Banales, J. M.; Masyuk, T. V.; Radtke, B.; Splinter, P. L.; La Russo, N. F. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299(4), G990-G999.
116. Masyuk, T.; Masyuk, A.; La Russo, N. Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr. Opin. Gastroenterol., 2009, 25(3), 265-271.
117. Jung, D.; York, J. P.; Wang, L.; Yang, C.; Zhang, A.; Francis, H. L.; Webb, P.; McKeehan, W. L.; Alpini, G.; Lesage, G. D.; Moore, D. D.; Xia, X. FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. Pflugers Arch., 2014, 466(5), 1011-1019.
118. Lazaridis, K. N.; Pham, L.; Tietz, P.; Marinelli, R. A.; De Groen, P. C.; Levine, S.; Dawson, P. A.; La Russo, N. F. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J. Clin. Invest., 1997, 100(11), 2714-2721.
119. +-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology, 1997, 113(5), 1734-1740.
120. Lazaridis, K. N.; Tietz, P.; Wu, T.; Kip, S.; Dawson, P. A.; La Russo, N. F. Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. Proc. Natl Acad. Sci. U. S. A., 2000, 97(20), 11092-11097.
121. Scheffer, G. L.; Kool, M.; De Haas, M.; De Vree, J. M.; Pijnenborg, A. C.; Bosman, D. K.; Elferink, R. P.; Van Der Valk, P.; Borst, P.; Scheper, R J. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest, 2002, 82(2), 193-201.
122. Ballatori, N.; Christian, W. V.; Lee, J. Y.; Dawson, P. A.; Soroka, C. J.; Boyer, J. L.; Madejczyk, M. S.; Li, N. OSTa-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology, 2005, 42(6), 1270-1279.
123. + transport in ursodeoxycholate-induced biliary HCO3 secretion in the rat. Am. J. Physiol. Gastrointest. Liver Physiol, 1985, 249(3), G335-G341.
124. Garcia-Marin, J. J.; Dumont, M.; Corbic, M.; De Couet, G.; Erlinger, S. Effect of acid-base balance and acetazolamide on ursodeoxycholate-induced biliary bicarbonate secretion. Am. J. Physiol. Gastrointest. Liver Physiol, 1985, 248(1), G20-G27.
125. Alpini, G.; Ueno, Y.; Glaser, S. S.; Marzioni, M.; Phinizy, J. L.; Francis, H.; Lesage, G. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. Hepatology, 2001, 34(5), 868-876.
126. Munoz-Garrido, P.; Marin, J. J.; Perugorria, M. J.; Urribarri, A. D.; Erice, O.; Saez, E.; Uriz, M.; Sarvide, S.; Portu, A.; Concepcion, A. R.; Romero, M. R.; Monte, M. J.; Santos-Laso, A.; Hijona, E.; Jimenez-Aguero, R.; Marzioni, M.; Beuers, U.; Masyuk, T. V.; La Russo, N. F.; Prieto, J.; Bujanda, L.; Drenth, J. P.; Banales, J. M. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J. Hepatol, 2015, 63(4), 952-961.
127. Uriz, M.; Saez, E.; Prieto, J.; Medina, J. F.; Banales, J. M. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS One, 2011, 6(12), e28717.
128. Prieto, J.; Garcia, N.; Marti-Climent, J. M.; Penuelas, I.; Richter, J. A.; Medina, J. F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology, 1999, 117(1), 167-172.
129. Dumont, M.; Erlinger, S.; Uchman, S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology, 1980, 79(1), 82-89.
130. Marzioni, M.; Ueno, Y.; Glaser, S.; Francis, H.; Benedetti, A.; Alvaro, D.; Venter, J.; Fava, G.; Alpini, G. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver Int., 2007, 27(4), 558-568.
131. Marucci, L.; Alpini, G.; Glaser, S. S.; Alvaro, D.; Benedetti, A.; Francis, H.; Phinizy, J. L.; Marzioni, M.; Mauldin, J.; Venter, J.; Baumann, B.; Ugili, L.; Le Sage, G. Taurocholate feeding prevents CCl4-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol, 2003, 284(2), G290-G301.
132. Keitel, V.; Ullmer, C; Haussinger, D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol. Chem., 2010, 391(7), 785-789.
133. Keitel, V.; Haussinger, D. TGR5 in the biliary tree. Dig. Dis., 2011, 29(1), 45-47.
134. Keitel, V.; Haussinger, D. TGR5 in cholangiocytes. Curr. Opin. Gastroenterol, 2013, 29(3), 299-304.
135. Masyuk, T. V.; Masyuk, A. I.; La Russo, N. F. TGR5 in the Cholangiociliopathies. Dig. Dis., 2015, 33(3), 420-425.
136. - output. Hepatology, 2011, 54(4), 1303-1312.
137. Hirschfield, G. M.; Mason, A.; Luketic, V.; Lindor, K.; Gordon, S. C.; Mayo, M.; Kowdley, K. V.; Vincent, C; Bodhenheimer, H. C., Jr.; Pares, A.; Trauner, M.; Marschall, H. U.; Adorini, L.; Sciacca, C.; Beecher-Jones, T.; Castelloe, E.; Bohm, O.; Shapiro, D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 2015, 148(4), 751-761.
138. Beuers, U.; Kremer, A. E.; Bolier, R.; Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology, 2014, 60(1), 399-407.
139. Angelin, B.; Bjorkhem, I.; Einarsson, K.; Ewerth, S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J. Clin. Invest., 1982, 70(4), 724-731.
140. Weiner, I. M.; Glasser, J. E.; Lack, L. Renal excretion of bile bcids: taurocholic, glycocholic, and colic acids. Am. J. Physiol. 1964, 207, 964-70.
141. Lee, J.; Azzaroli, F.; Wang, L.; Soroka, C. J.; Gigliozzi, A.; Setchell, K. D.; Kramer, W.; Boyer, J. L. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology, 2001, 121(6), 1473-1484.
142. Huls, M.; Brown, C. D.; Windass, A. S.; Sayer, R.; Van Den Heuvel, J. J.; Heemskerk, S.; Russel, F. G.; Masereeuw, R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int., 2008, 73(2), 220-225.
143. Schlattjan, J. H.; Winter, C.; Greven, J. Regulation of renal tubular bile acid transport in the early phase of an obstructive cholestasis in the rat. Nephron. Physiol., 2003, 95(3), 49-56.
144. Mennone, A.; Soroka, C. J.; Harry, K. M.; Boyer, J. L. Role of breast cancer resistance protein in the adaptive response to cholestasis. Drug Metab. Dispos., 2010, 38(10), 1673-1678.
145. Wang, L.; Hartmann, P.; Haimerl, M.; Bathena, S. P.; Sjowall, C.; Almer, S.; Alnouti, Y.; Hofmann, A. F.; Schnabl, B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J. Hepatol., 2014, 60(6), 1259-1267.
146. Alnouti, Y. Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol. Sci., 2009, 108(2), 225-246.
147. Stiehl, A.; Earnest, D. L.; Admirant, W. H. Sulfation and renal excretion of bile salts in patients with cirrhosis of the liver. Gastroenterology, 1975, 68(3), 534-544.
148. Summerfield, J. A.; Cullen, J.; Barnes, S.; Billing, B. H. Evidence for renal control of urinary excretion of bile acids and bile acid sulphates in the cholestatic syndrome. Clin. Sci. Mol. Med., 1977, 52(1), 51-65.
149. Mackenzie, P. I.; Rogers, A.; Treloar, J.; Jorgensen, B. R.; Miners, J. O.; Meech, R. Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J. Biol. Chem., 2008, 283(52), 36205-36210.
150. Marschall, H. U.; Griffiths, W. J.; Gotze, U.; Zhang, J.; Wietholtz, H.; Busch, N.; Sjovall, J.; Matern, S. The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. Hepatology, 1994, 20(4), 845-853.
151. Kobayashi, N.; Kubota, K.; Oiwa, H.; Goto, J.; Niwa, T.; Kobayashi, K. Idiotype-anti-idiotype-based noncompetitive enzyme-linked immunosorbent assay of ursodeoxycholic acid 7-N-acetylglucosaminides in human urine with subfemtomole range sensitivity. J. Immunol. Meth., 2003, 272(1-2), 1-10.
152. Meech, R.; Mubarokah, N.; Shivasami, A.; Rogers, A.; Nair, P. C.; Hu, D. G.; McKinnon, R. A.; Mackenzie, P. I. A novel function for UDP glycosyltransferase 8: galactosidation of bile acids. Mol. Pharmacol., 2015, 87(3), 442-450.
153. Marin, J. J.; Macias, R. I.; Serrano, M. A. The hepatobiliary-like excretory function of the placenta. A review. Placenta, 2003, 24(5), 431-438.
154. Macias, R. I.; Marin, J. J.; Serrano, M. A. Excretion of biliary compounds during intrauterine life. World J. Gastroenterol., 2009, 15(7), 817-828.
155. Marin, J. J.; Serrano, M. A.; El-Mir, M. Y.; Eleno, N.; Boyd, C. A. Bile acid transport by basal membrane vesicles of human term placental trophoblast. Gastroenterology, 1990, 99(5), 1431-1438.
156. Bravo, P.; Marin, J. J.; Beveridge, M. J.; Novak, D. A. Reconstitution and characterization of ATP-dependent bile acid transport in human and rat placenta. Biochem. J., 1995, 311(2), 479-485.
157. Briz, O.; Serrano, M. A.; MacIas, R. I.; Gonzalez-Gallego, J.; Marin, J. J. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J., 2003, 371(3), 897-905.
158. Patel, P.; Weerasekera, N.; Hitchins, M.; Boyd, C. A.; Johnston, D. G.; Williamson, C. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C, OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta, 2003, 24(1), 39-44.
159. Sato, K.; Sugawara, J.; Sato, T.; Mizutamari, H.; Suzuki, T.; Ito, A.; Mikkaichi, T.; Onogawa, T.; Tanemoto, M.; Unno, M.; Abe, T.; Okamura, K. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta, 2003, 24(2-3), 144-148.
160. Serrano, M. A.; Macias, R. I.; Briz, O.; Monte, M. J.; Blazquez, A. G.; Williamson, C.; Kubitz, R.; Marin, J. J. Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta, 2007, 28(2-3), 107-117.
161. St-Pierre, M. V.; Serrano, M. A.; Macias, R. I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P. J.; Marin, J. J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(4), R1495-R1503.
162. Azzaroli, F.; Mennone, A.; Feletti, V.; Simoni, P.; Baglivo, E.; Montagnani, M.; Rizzo, N.; Pelusi, G. D. E.; Aloysio D.; Lodato, F.; Festi, D.; Colecchia, A.; Roda, E.; Boyer, J. L.; Mazzella, G. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment. Pharmacol. Ther., 2007, 26(8), 1139-1146.
163. Ceckova, M.; Libra, A.; Pavek, P.; Nachtigal, P.; Brabec, M.; Fuchs, R.; Staud, F. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin. Exp. Pharmacol. Physiol., 2006, 33(1-2), 58-65.
164. Janvilisri, T.; Shahi, S.; Venter, H.; Balakrishnan, L.; Van Veen, H. W. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem. J., 2005, 385(Pt 2), 419-426.
165. Monte, M. J.; Rodriguez-Bravo, T.; Macias, R. I.; Bravo, P.; El-Mir, M. Y.; Serrano, M. A.; Lopez-Salva, A.; Marin, J. J. Relationship between bile acid transplacental gradients and transport across the fetal-facing plasma membrane of the human trophoblast. Pediatr. Res., 1995, 38(2), 156-163.
166. Estiu, M. C.; Monte, M. J.; Rivas, L.; Moiron, M.; Gomez-Rodriguez, L.; Rodriguez-Bravo, T.; Marin, J. J.; Macias, R. I. Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy. Br. J. Clin. Pharmacol., 2015, 79(2), 316-329.
167. Macias, R. I.; Pascual, M. J.; Bravo, A.; Alcalde, M. P.; Larena, M. G.; St-Pierre, M. V.; Serrano, M. A.; Marin, J. J. Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem. Hepatology, 2000, 31(4), 975-983.
168. Serrano, M. A.; Macias, R. I.; Vallejo, M.; Briz, O.; Bravo, A.; Pascual, M. J.; St-Pierre, M. V.; Stieger, B.; Meier, P. J.; Marin, J. J. Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J. Pharmacol. Exp. Ther., 2003, 305(2), 515-524.
169. Hakkola, J.; Raunio, H.; Purkunen, R.; Pelkonen, O.; Saarikoski, S.; Cresteil, T.; Pasanen, M. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol., 1996, 52(2), 379-383.
170. Marin, J. J.; Macias, R. I.; Briz, O.; Perez, M. J.; Blazquez, A. G.; Arrese, M.; Serrano, M. A. Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. Liver Int., 2008, 28(4), 435-454.
171. Prouillac, C.; Lecoeur, S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab. Dispos., 2010, 38(10), 1623-1635.
172. Shuster, D. L.; Bammler, T. K.; Beyer, R. P.; MacDonald, J. W.; Tsai, J. M.; Farin, F. M.; Hebert, M. F.; Thummel, K. E.; Mao, Q. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab. Dispos., 2013, 41(2), 332-342.
173. Mullally, B. A.; Hansen, W. F. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet. Gynecol. Surv., 2002, 57(1), 47-52.
174. Zecca, E.; De Luca, D.; Baroni, S.; Vento, G.; Tiberi, E.; Romagnoli, C. Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. Pediatrics, 2008, 121(1), e146-9.
175. De Luca, D.; Minucci, A.; Zecca, E.; Piastra, M.; Pietrini, D.; Carnielli, V. P.; Zuppi, C; Tridente, A.; Conti, G.; Capoluongo, E. D. Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration. Intensive Care Med., 2009, 35(2), 321-326.
176. Herraez, E.; Lozano, E.; Poli, E.; Keitel, V.; De Luca, D.; Williamson, C; Marin, J. J.; Macias, R. I. Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. J. Mol. Med. (Berl), 2014, 92(4), 359-372.
177. Zhao, Y. D.; Yun, H. Z.; Peng, J.; Yin, L.; Chu, L.; Wu, L.; Michalek, R.; Liu, M.; Keshavjee, S.; Waddell, T.; Granton, J.; De Perrot, M. De novo synthesize of bile acids in pulmonary arterial hypertension lung. Metabolomics, 2014, 10(6), 1169-1175.
178. Watanabe, M.; Houten, S. M.; Mataki, C; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 2006, 439(7075), 484-489.
179. Teodoro, J. S.; Zouhar, P.; Flachs, P.; Bardova, K.; Janovska, P.; Gomes, A. P.; Duarte, F. V.; Varela, A. T.; Rolo, A. P.; Palmeira, CM.; Kopecky, J. Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice. Int. J. Obes. (Lond), 2014, 38(8), 1027-1034.
180. Fang, S.; Suh, J. M.; Reilly, S. M.; Yu, E.; Osborn, O.; Lackey, D.; Yoshihara, E.; Perino, A.; Jacinto, S.; Lukasheva, Y.; Atkins, A. R.; Khvat, A.; Schnabl, B.; Yu, R. T.; Brenner, D. A.; Coulter, S.; Liddle, C; Schoonjans, K.; Olefsky, J. M.; Saltiel, A. R.; Downes, M.; Evans, R. M. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med., 2015, 21(2), 159-165.
181. Wecksler, W. R.; Norman, A. W. Studies on the mode of action of calciferol XXV. 1α, 25-dihydroxy-5, 6-trans-vitamin D3, the 5E-isomer of 1α, 25-dihydroxyvitamin D3. Steroids, 1980, 35(4), 419-425.
182. Makishima, M.; Lu, T. T.; Xie, W.; Whitfield, G. K.; Domoto, H.; Evans, R. M.; Haussler, M. R.; Mangelsdorf, D. J. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002, 296(5571), 1313-1316.
183. Schmiedlin-Ren, P.; Thummel, K. E.; Fisher, J. M.; Paine, M. F.; Watkins, P. B. Induction of CYP3A4 by 1α, 25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab. Dispos., 2001, 29(11), 1446-1453.
184. Pascussi, J. M.; Gerbal-Chaloin, S.; Drocourt, L.; Maurel, P.; Vilarem, M. J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta, 2003, 1619(3), 243-253.
185. Chatterjee, B.; Echchgadda, I.; Song, C. S. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol, 2005, 400, 165-191.
186. McCarthy, T. C.; Li, X.; Sinal, C. J. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J. Biol. Chem., 2005, 280(24), 23232-23242.
187. Chen, X.; Chen, F.; Liu, S.; Glaeser, H.; Dawson, P. A.; Hofmann, A. F.; Kim, R. B.; Shneider, B. L.; Pang, K. S. Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1α, 25-dihydroxyvitamin D3 via the vitamin D receptor. Mol. Pharmacol, 2006, 69(6), 1913-1923.
188. Han, S.; Chiang, J. Y. Mechanism of vitamin D receptor inhibition of cholesterol 7α-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos., 2009, 37(3), 469-478.
189. 3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver In vivo. Biopharm. Drug Dispos., 2009, 30(8), 457-475.
190. Schmidt, D. R.; Holmstrom, S. R.; Fon Tacer, K.; Bookout, A. L.; Kliewer, S. A.; Mangelsdorf, D. J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem., 2010, 285(19), 14486-14494.
191. Ogura, M.; Nishida, S.; Ishizawa, M.; Sakurai, K.; Shimizu, M.; Matsuo, S.; Amano, S.; Uno, S.; Makishima, M. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther., 2009, 328(2), 564-570.
192. Kliewer, S. A.; Willson, T. M. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res., 2002, 43(3), 359-364.
193. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klaassen, CD.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(6), 3369-3374.
194. Wistuba, W.; Gnewuch, C; Liebisch, G.; Schmitz, G.; Langmann, T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol, 2007, 13(31), 4230-4235.
195. Wang, H.; Venkatesh, M.; Li, H.; Goetz, R.; Mukherjee, S.; Biswas, A.; Zhu, L.; Kaubisch, A.; Wang, L.; Pullman, J.; Whitney, K.; Kuroo, M.; Roig, A. I.; Shay, J. W.; Mohammadi, M.; Mani, S. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J. Clin. Invest., 2011, 121(8), 3220-3232.
196. Stedman, C. A.; Liddle, C; Coulter, S. A.; Sonoda, J.; Alvarez, J. G.; Moore, D. D.; Evans, R. M.; Downes, M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(6), 2063-2068.
197. Guo, G. L.; Lambert, G.; Negishi, M.; Ward, J. M.; Brewer, H. B., Jr.; Kliewer, S. A.; Gonzalez, F. J.; Sinal, C. J. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem., 2003, 278(46), 45062-45071.
198. Xie, W.; Radominska-Pandya, A.; Shi, Y.; Simon, CM.; Nelson, M. C; Ong, E. S.; Waxman, D. J.; Evans, R. M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(6), 3375-3380.
199. Cheng, J.; Fang, Z. Z.; Kim, J. H.; Krausz, K. W.; Tanaka, N.; Chiang, J. Y.; Gonzalez, F. J. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J. Lipid Res., 2014, 55(3), 455-465.
200. Saini, S. P.; Sonoda, J.; Xu, L.; Toma, D.; Uppal, H.; Mu, Y.; Ren, S.; Moore, D. D.; Evans, R. M.; Xie, W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol, 2004, 65(2), 292-300.
201. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284(5418), 1365-1368.
202. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284(5418), 1362-1365.
203. Grober, J.; Zaghini, I.; Fujii, H.; Jones, S. A.; Kliewer, S. A.; Willson, T. M.; Ono, T.; Besnard, P. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem., 1999, 274(42), 29749-29754.
204. Potthoff, M. J.; Boney-Montoya, J.; Choi, M.; He, T.; Sunny, N. E.; Satapati, S.; Suino-Powell, K.; Xu, H. E.; Gerard, R. D.; Finck, B. N.; Burgess, S. C; Mangelsdorf, D. J.; Kliewer, S. A. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab., 2011, 13(6), 729-738.
205. Zhang, L.; Wang, Y. D.; Chen, W. D.; Wang, X.; Lou, G.; Liu, N.; Lin, M.; Forman, B. M.; Huang, W. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology, 2012, 56(6), 2336-2343.
206. Li, F.; Jiang, C; Krausz, K. W.; Li, Y.; Albert, I.; Hao, H.; Fabre, K. M.; Mitchell, J. B.; Patterson, A. D.; Gonzalez, F. J. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 2013, 4, 2384.
207. Vaquero, J.; Briz, O.; Herraez, E.; Muntane, J.; Marin, J. J. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim. Biophys. Acta, 2013, 1833(10), 2212-2219.
208. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J. M.; Gonzalez, F J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis, 2007, 28(5), 940-946.
209. Vaquero, J.; Monte, M. J.; Dominguez, M.; Muntane, J.; Marin, JJ. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem. Pharmacol, 2013, 86(7), 926-939.
210. Lew, J. L.; Zhao, A.; Yu, J.; Huang, L.; De Pedro, N.; Pelaez, F.; Wright, S. D.; Cui, J. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem., 2004, 279(10), 8856-8861.
211. Sayin, S. I.; Wahlstrom, A.; Felin, J.; Jantti, S.; Marschall, H. U.; Bamberg, K.; Angelin, B.; Hyotylainen, T.; Oresic, M.; Backhed, F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-P-muricholic acid, a naturally occurring FXR antagonist. Cell Metab., 2013, 17(2), 225-235.
212. Rosales, R.; Romero, M. R.; Vaquero, J.; Monte, M. J.; Requena, P.; Martinez-Augustin, O.; Sanchez De Medina, F.; Marin, JJ. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. Biochem. Pharmacol, 2013, 85(6), 829-838.
213. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell, 1999, 3(5), 543-553.
214. Lu, T. T.; Makishima, M.; Repa, JJ.; Schoonjans, K.; Kerr, T. A.; Auwerx, J.; Mangelsdorf, D. J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell, 2000, 6(3), 507-515.
215. Kim, I.; Ahn, S. H.; Inagaki, T.; Choi, M.; Ito, S.; Guo, G. L.; Kliewer, S. A.; Gonzalez, F. J., Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res., 2007, 48(12), 2664-2672.
216. Lee, Y. K.; Schmidt, D. R.; Cummins, C. L.; Choi, M.; Peng, L.; Zhang, Y.; Goodwin, B.; Hammer, R. E.; Mangelsdorf, D. J.; Kliewer, S. A. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol, 2008, 22(6), 1345-1356.
217. Zweers, S. J.; Booij, K. A.; Komuta, M.; Roskams, T.; Gouma, D. J.; Jansen, P. L.; Schaap, F. G. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology, 2012, 55(2), 575-583.
218. Choi, M.; Moschetta, A.; Bookout, A. L.; Peng, L.; Umetani, M.; Holmstrom, S. R.; Suino-Powell, K.; Xu, H. E.; Richardson, J. A.; Gerard, R. D.; Mangelsdorf, D. J.; Kliewer, S. A. Identification of a hormonal basis for gallbladder filling. Nat. Med., 2006, 12(11), 1253-1255.
219. Bhatnagar, S.; Damron, H. A.; Hillgartner, F. B., Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem., 2009, 284(15), 10023-10033.
220. Denson, L. A.; Sturm, E.; Echevarria, W.; Zimmerman, T. L.; Makishima, M.; Mangelsdorf, D. J.; Karpen, S. J., The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology, 2001, 121(1), 140-147.
221. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D. J.; Suchy, F. J., Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem., 2001, 276(31), 28857-28865.
222. Landrier, J. F.; Eloranta, J. J.; Vavricka, S. R.; Kullak-Ublick, G. A., The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes. Am. J. Physiol. Gastrointest. Liver Physiol, 2006, 290(3), G476-G485.
223. Wagner, M.; Fickert, P.; Zollner, G.; Fuchsbichler, A.; Silbert, D.; Tsybrovskyy, O.; Zatloukal, K.; Guo, G. L.; Schuetz, J. D.; Gonzalez, F. J.; Marschall, H. U.; Denk, H.; Trauner, M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology, 2003, 125(3), 825-838.
224. Neimark, E.; Chen, F.; Li, X.; Shneider, B. L. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology, 2004, 40(1), 149-156.
225. Lee, H.; Zhang, Y.; Lee, F. Y.; Nelson, S. F.; Gonzalez, F. J.; Edwards, P. A. FXR regulates organic solute transportersa andβ in the adrenal gland, kidney, and intestine. J. Lipid Res., 2006, 47(1), 201-214.
226. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 2002, 298(5), 714-719.
227. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem., 2003, 278(11), 9435-9440.
228. Keitel, V.; Donner, M.; Winandy, S.; Kubitz, R.; Haussinger, D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun., 2008, 372(1), 78-84.
229. Keitel, V.; Spomer, L.; Marin, J. J.; Williamson, C; Geenes, V.; Kubitz, R.; Haussinger, D.; Macias, R. I. Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta, 2013, 34(9), 810-816.
230. Yasuda, H.; Hirata, S.; Inoue, K.; Mashima, H.; Ohnishi, H.; Yoshiba, M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem. Biophys. Res. Commun., 2007, 354(1), 154-159.
231. Wang, Y. D.; Chen, W. D.; Yu, D.; Forman, B. M.; Huang, W. The G-protein-coupled bile acid receptor, Gpbar1(TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology, 2011, 54(4), 1421-1432.
232. Keitel, V.; Gorg, B.; Bidmon, H. J.; Zemtsova, I.; Spomer, L.; Zilles, K.; Haussinger, D. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia, 2010, 58(15), 1794-1805.
233. Kumar, D. P.; Rajagopal, S.; Mahavadi, S.; Mirshahi, F.; Grider, J. R.; Murthy, K. S.; Sanyal, A. J. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreaticβ cells. Biochem. Biophys. Res. Commun., 2012, 427(3), 600-605.
234. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun., 2005, 329(1), 386-390.
235. Thomas, C; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C; Pruzanski, M.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab., 2009, 10(3), 167-177.
236. Harach, T.; Pols, T. W.; Nomura, M.; Maida, A.; Watanabe, M.; Auwerx, J.; Schoonjans, K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep., 2012, 2, 430.
237. Aouadi, M.; Tencerova, M.; Vangala, P.; Yawe, J. C.; Nicoloro, S. M.; Amano, S. U.; Cohen, J. L.; Czech, M. P. Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proc. Natl. Acad. Sci. U. S. A., 2013, 110(20), 8278-8283.
238. Perino, A.; Pols, T. W.; Nomura, M.; Stein, S.; Pellicciari, R.; Schoonjans, K. TGR5 reduces macrophage migration through mTOR-induced C/EBPP differential translation. J. Clin. Invest., 2014, 124(12), 5424-5436.
239. Pols, T. W.; Noriega, L. G.; Nomura, M.; Auwerx, J.; Schoonjans, K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol, 2011, 54(6), 1263-1272.
240. Scott-Conner, C. E.; Grogan, J. B. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J. Surg. Res., 1994, 57(2), 316-336.
241. Pain, J. A.; Bailey, M. E. Prevention of endotoxaemia in obstructive jaundice-a comparative study of bile salts. HPB Surg., 1988, 1(1), 21-27.
242. Hov, J. R.; Keitel, V.; Laerdahl, J. K.; Spomer, L.; Ellinghaus, E.; ElSharawy, A.; Melum, E.; Boberg, K. M.; Manke, T.; Balschun, T.; Schramm, C; Bergquist, A.; Weismuller, T.; Gotthardt, D.; Rust, C; Henckaerts, L.; Onnie, CM.; Weersma, R. K.; Sterneck, M.; Teufel, A.; Runz, H.; Stiehl, A.; Ponsioen, C. Y.; Wijmenga, C; Vatn, M. H.; Stokkers, P. C.; Vermeire, S.; Mathew, C. G.; Lie, B. A.; Beuers, U.; Manns, M. P.; Schreiber, S.; Schrumpf, E.; Haussinger, D.; Franke, A.; Karlsen, T. H. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One, 2010, 5(8), e12403.
243. Keitel, V.; Reinehr, R.; Gatsios, P.; Rupprecht, C; Gorg, B.; Selbach, O.; Haussinger, D.; Kubitz, R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology, 2007, 45(3), 695-704.
244. Keitel, V.; Cupisti, K.; Ullmer, C; Knoefel, W. T.; Kubitz, R.; Haussinger, D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology, 2009, 50(3), 861-870.
245. Lavoie, B.; Balemba, O. B.; Godfrey, C; Watson, C. A.; Vassileva, G.; Corvera, C. U.; Nelson, M. T.; Mawe, G. M. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J. Physiol., 2010, 588(17), 3295-3305.
246. Poole, D. P.; Godfrey, C; Cattaruzza, F.; Cottrell, G. S.; Kirkland, J. G.; Pelayo, J. C.; Bunnett, N. W.; Corvera, C. U. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol. Motil, 2010, 22(7), 814-25, e227-8.
247. Rajagopal, S.; Kumar, D. P.; Mahavadi, S.; Bhattacharya, S.; Zhou, R.; Corvera, C. U.; Bunnett, N. W.; Grider, J. R.; Murthy, K. S. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am. J. Physiol. Gastrointest. Liver Physiol, 2013, 304(5), G527-G535.
248. Alemi, F.; Poole, D. P.; Chiu, J.; Schoonjans, K.; Cattaruzza, F.; Grider, J. R.; Bunnett, N. W.; Corvera, C. U. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology, 2013, 144(1), 145-154.
249. Bunnett, N. W. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J. Physiol, 2014, 592(Pt 14), 2943-2950.
250. Bove, K. E.; Heubi, J. E.; Balistreri, W. F.; Setchell, K. D. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr. Dev. Pathol, 2004, 7(4), 315-334.
251. Fischler, B.; Bodin, K.; Stjernman, H.; Olin, M.; Hansson, M.; Sjovall, J.; Bjorkhem, I. Cholestatic liver disease in adults may be due to an inherited defect in bile acid biosynthesis. J. Intern. Med., 2007, 262(2), 254-262.
252. Stieger, B.; Zhang, J.; O'Neill, B.; Sjovall, J.; Meier, P. J. Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. Eur. J. Biochem., 1997, 244(1), 39-44.
253. Zhang, W.; Jha, P.; Wolfe, B.; Gioiello, A.; Pellicciari, R.; Wang, J.; Heubi, J.; Setchell, K. D. Tandem mass spectrometric determination of atypical 3P-hydroxy-85-bile acids in patients with 3P-hydroxy-85-C27-steroid oxidoreductase deficiency: Application to diagnosis and monitoring of bile acid therapeutic response. Clin. Chem., 2015, 61(7):955-963.
254. Pullinger, C. R.; Eng, C; Salen, G.; Shefer, S.; Batta, A. K.; Erickson, S. K.; Verhagen, A.; Rivera, C. R.; Mulvihill, S. J.; Malloy, M. J.; Kane, J. P. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest., 2002, 110(1), 109-117.
255. Setchell, K. D.; Schwarz, M.; O'Connell, N. C.; Lund, E. G.; Davis, D. L.; Lathe, R.; Thompson, H. R.; Weslie Tyson, R.; Sokol, R. J.; Russell, D. W. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest., 1998, 102(9), 1690-1703.
256. Jacquemin, E.; Setchell, K. D.; O'Connell, N. C.; Estrada, A.; Maggiore, G.; Schmitz, J.; Hadchouel, M.; Bernard, O. A new cause of progressive intrahepatic cholestasis: 3β-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J. Pediatr. 1994, 125(3), 379-384.
257. Cheng, J. B.; Jacquemin, E.; Gerhardt, M.; Nazer, H.; Cresteil, D.; Heubi, J. E.; Setchell, K. D.; Russell, D. W. Molecular genetics of 3β-hydroxy-85-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J. Clin. Endocrinol. Metab., 2003, 88(4), 1833-1841.
258. Mizuochi, T.; Kimura, A.; Ueki, I.; Takahashi, T.; Hashimoto, T.; Takao, A.; Seki, Y.; Takei, H.; Nittono, H.; Kurosawa, T.; Matsuishi, T. Molecular genetic and bile acid profiles in two Japanese patients with 3P-hydroxy-85-C27-steroid dehydrogenase/isomerase deficiency. Pediatr. Res., 2010, 68(3), 258-263.
259. Setchell, K. D.; Suchy, F. J.; Welsh, M. B.; Zimmer-Nechemias, L.; Heubi, J.; Balistreri, W. F. A 4-3-oxosteroid 5β-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. J. Clin. Invest., 1988, 82(6), 2148-2157.
260. Ferdinandusse, S.; Denis, S.; Faust, P. L.; Wanders, R. J. Bile acids: the role of peroxisomes. J. Lipid Res., 2009, 50(11), 2139-2147.
261. Cali, J. J.; Hsieh, C. L.; Francke, U.; Russell, D. W. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem., 1991, 266(12), 7779-7783.
262. Shimazu, K.; Kuwabara, M.; Yoshii, M.; Kihira, K.; Takeuchi, H.; Nakano, I.; Ozawa, S.; Onuki, M.; Hatta, Y.; Hoshita, T. Bile alcohol profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis. J. Biochem., 1986, 99(2), 477-483.
263. Batta, A. K.; Salen, G.; Shefer, S.; Tint, G. S.; Batta, M. Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. J. Lipid Res., 1987, 28(8), 1006-1012.
264. Clayton, P. T.; Verrips, A.; Sistermans, E.; Mann, A.; Mieli-Vergani, G.; Wevers, R. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J. Inherit. Metab. Dis., 2002, 25(6), 501-513.
265. Ferdinandusse, S.; Overmars, H.; Denis, S.; Waterham, H. R.; Wanders, R. J.; Vreken, P. Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomala-methylacyl-CoA racemase deficiency. J. Lipid Res., 2001, 42(1), 137-141.
266. Setchell, K. D.; Heubi, J. E.; Bove, K. E.; O'Connell, N. C.; Brewsaugh, T.; Steinberg, S. J.; Moser, A.; Squires, R. H., Jr. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology, 2003, 124(1), 217-232.
267. Wanders, R. J. Metabolic functions of peroxisomes in health and disease. Biochimie, 2014, 98, 36-44.
268. Monnens, L.; Bakkeren, J.; Parmentier, G.; Janssen, G.; Van Haelst, U.; Trijbels, F.; Eyssen, H. Disturbances in bile acid metabolism of infants with the Zellweger (cerebro-hepato-renal) syndrome. Eur. J. Pediatr., 1980, 133(1), 31-35.
269. Kase, B. F.; Pedersen, J. I.; Strandvik, B.; Bjorkhem, I. In vivo and vitro studies on formation of bile acids in patients with Zellweger syndrome. Evidence that peroxisomes are of importance in the normal biosynthesis of both cholic and chenodeoxycholic acid. J. Clin. Invest., 1985, 76(6), 2393-2402.
270. Ferdinandusse, S.; Jimenez-Sanchez, G.; Koster, J.; Denis, S.; Van Roermund, C. W.; Silva-Zolezzi, I.; Moser, A. B.; Visser, W. F.; Gulluoglu, M.; Durmaz, O.; Demirkol, M.; Waterham, H. R.; Gokcay, G.; Wanders, R. J.; Valle, D. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Hum. Mol. Genet., 2015, 24(2), 361-370.
271. Ferdinandusse, S.; Denis, S.; Dacremont, G.; Wanders, R. J. Toxicity of peroxisomal C27-bile acid intermediates. Mol. Genet. Metab., 2009, 96(3), 121-128.
272. Carlton, V. E.; Harris, B. Z.; Puffenberger, E. G.; Batta, A. K.; Knisely, A. S.; Robinson, D. L.; Strauss, K. A.; Shneider, B. L.; Lim, W. A.; Salen, G.; Morton, D. H.; Bull, L. N. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat. Genet, 2003, 34(1), 91-96.
273. Setchell, K. D.; Heubi, J. E.; Shah, S.; Lavine, J. E.; Suskind, D.; Al-Edreesi, M.; Potter, C; Russell, D. W.; O'Connell, N. C.; Wolfe, B.; Jha, P.; Zhang, W.; Bove, K. E.; Knisely, A. S.; Hofmann, A. F.; Rosenthal, P.; Bull, L. N. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency. Gastroenterology, 2013, 144(5), 945-955.
274. Heubi, J. E.; Setchell, K. D.; Jha, P.; Buckley, D.; Zhang, W.; Rosenthal, P.; Potter, C; Horslen, S.; Suskind, D. Treatment of bile acid amidation defects with glycocholic acid. Hepatology, 2015, 61(1), 268-274.
275. Chong, C. P.; Mills, P. B.; McClean, P.; Gissen, P.; Bruce, C; Stahlschmidt, J.; Knisely, A. S.; Clayton, P. T. Bile acid-CoA ligase deficiency - a new inborn error of bile acid metabolism. J. Inherit. Metab. Dis., 2012, 35(3), 521-530.
276. Ho, R. H.; Leake, B. F.; Roberts, R. L.; Lee, W.; Kim, R. B. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J. Biol. Chem., 2004, 279(8), 7213-7222.
277. Erlinger, S. NTCP deficiency: a new inherited disease of bile acid transport. Clin. Res. Hepatol. Gastroenterol., 2015, 39(1), 7-8.
278. Kubitz, R.; Keitel, V.; Haussinger, D. Inborn errors of biliary canalicular transport systems. Methods Enzymol., 2005, 400, 558-569.
279. Jacquemin, E. Progressive familial intrahepatic cholestasis. Clin. Res. Hepatol. Gastroenterol., 2012, 36(Suppl 1), S26-S35.
280. Eloranta, M. L.; Hakli, T.; Hiltunen, M.; Helisalmi, S.; Punnonen, K.; Heinonen, S. Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand. J. Gastroenterol., 2003, 38(6), 648-652.
281. Keitel, V.; Vogt, C.; Haussinger, D.; Kubitz, R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology, 2006, 131(2), 624-629.
282. Chen, F.; Ananthanarayanan, M.; Emre, S.; Neimark, E.; Bull, L. N.; Knisely, A. S.; Strautnieks, S. S.; Thompson, R. J.; Magid, M. S.; Gordon, R.; Balasubramanian, N.; Suchy, F. J.; Shneider, B. L. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology, 2004, 126(3), 756-764.
283. Alvarez, L.; Jara, P.; Sanchez-Sabate, E.; Hierro, L.; Larrauri, J.; Diaz, M. C.; Camarena, C.; De La Vega, A.; Frauca, E.; Lopez-Collazo, E.; Lapunzina, P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet., 2004, 13(20), 2451-2460.
284. Attili, A. F.; Angelico, M.; Cantafora, A.; Alvaro, D.; Capocaccia, L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med. Hypotheses, 1986, 19(1), 57-69.
285. Deleuze, J. F.; Jacquemin, E.; Dubuisson, C.; Cresteil, D.; Dumont, M.; Erlinger, S.; Bernard, O.; Hadchouel, M. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology, 1996, 23(4), 904-908.
286. Groen, A.; Romero, M. R.; Kunne, C.; Hoosdally, S. J.; Dixon, P. H.; Wooding, C.; Williamson, C.; Seppen, J.; Van Den Oever, K.; Mok, K. S.; Paulusma, C. C.; Linton, K. J.; Oude Elferink, R. P. Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology, 2011, 141(5), 1927-1937.
287. Gordo-Gilart, R.; Andueza, S.; Hierro, L.; Martinez-Fernandez, P.; D'Agostino, D.; Jara, P.; Alvarez, L. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut, 2015, 64(1), 147-155.
288. Sokol, R. J.; Devereaux, M.; Khandwala, R.; O'Brien, K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology, 1993, 17(5), 869-881.
289. Perez, M. J.; Macias, R. I.; Duran, C.; Monte, M. J.; Gonzalez-Buitrago, J. M.; Marin, J. J. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J. Hepatol., 2005, 43(2), 324-332.
290. Faubion, W. A.; Guicciardi, M. E.; Miyoshi, H.; Bronk, S. F.; Roberts, P. J.; Svingen, P. A.; Kaufmann, S. H.; Gores, G. J. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest., 1999, 103(1), 137-145.
291. Rodrigues, C. M.; Fan, G.; Wong, P. Y.; Kren, B. T.; Steer, C. J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol. Med., 1998, 4(3), 165-178.
292. Yerushalmi, B.; Dahl, R.; Devereaux, M. W.; Gumpricht, E.; Sokol, R. J. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology, 2001, 33(3), 616-626.
293. Song, P.; Zhang, Y.; Klaassen, C. D. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol. Sci., 2011, 123(2), 359-367.
294. Camilleri, M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver, 2015, 9(3), 332-339.
295. Ridlon, J. M.; Alves, J. M.; Hylemon, P. B.; Bajaj, J. S. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes, 2013, 4(5), 382-387.
296. Appleby, R. N.; Walters, J. R. The role of bile acids in functional GI disorders. Neurogastroenterol. Motil., 2014, 26(8), 1057-1069.
297. Boesjes, M.; Brufau, G. Metabolic effects of bile acids in the gut in health and disease. Curr. Med. Chem., 2014, 21(24), 2822-2829.
298. Cook, J. W.; Kennaway, E. L.; Kennaway, N. M. Production of tumors in mice by deoxycholic acid. Nature, 1940, 145, 627.
299. Monte, J. M.; Barbero, E. R.; Villanueva, G. R.; Serrano, M. A.; Marin, J. J. Role of rate-limiting enzymes of nucleotide metabolism in taurocholate-induced DNA synthesis inhibition. J. Hepatol., 1996, 25(2), 191-199.
300. Huang, W.; Ma, K.; Zhang, J.; Qatanani, M.; Cuvillier, J.; Liu, J.; Dong, B.; Huang, X.; Moore, D. D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science, 2006, 312(5771), 233-236.
301. Fan, M.; Wang, X.; Xu, G.; Yan, Q.; Huang, W. Bile acid signaling and liver regeneration. Biochim. Biophys. Acta, 2015, 1849(2), 196-200.
302. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D. D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 2007, 67(3), 863-867.
303. Degirolamo, C.; Modica, S.; Vacca, M.; Di Tullio, G.; Morgano, A.; D'Orazio, A.; Kannisto, K.; Parini, P.; Moschetta, A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology, 2015, 61(1), 161-170.
304. Martinez-Becerra, P.; Vaquero, J.; Romero, M. R.; Lozano, E.; Anadon, C.; Macias, R. I.; Serrano, M. A.; Grane-Boladeras, N.; Munoz-Bellvis, L.; Alvarez, L.; Sangro, B.; Pastor-Anglada, M.; Marin, J. J. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm., 2012, 9(6), 1693-1704.
305. Martinez-Becerra, P.; Monte, I.; Romero, M. R.; Serrano, M. A.; Vaquero, J.; Macias, R. I.; Del Rio, A.; Grane-Boladeras, N.; Jimenez, F.; San-Martin, F. G.; Pastor-Anglada, M.; Marin, J. J. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharmacol. Res., 2012, 66(5), 419-427.
306. Zimber, A.; Zusman, I.; Bentor, R.; Pinus, H. Effects of lithocholic acid exposure throughout pregnancy on late prenatal and early postnatal development in rats. Teratology, 1991, 43(4), 355-361.
307. Bernstein, H.; Bernstein, C.; Payne, C. M.; Dvorak, K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J. Gastroenterol., 2009, 15(27), 3329-3340.
308. Ajouz, H.; Mukherji, D.; Shamseddine, A. Secondary bile acids: an underrecognized cause of colon cancer. World J. Surg. Oncol., 2014, 12, 164.
309. Anakk, S.; Bhosale, M.; Schmidt, V. A.; Johnson, R. L.; Finegold, M. J.; Moore, D. D. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep., 2013, 5(4), 1060-1069.
310. Raju, U.; Levitz, M.; Javitt, N. B. Bile acids in human breast cyst fluid: the identification of lithocholic acid. J. Clin. Endocrinol. Metab., 1990, 70(4), 1030-1034.
311. Costarelli, V.; Sanders, T. A. Plasma deoxycholic acid concentration is elevated in postmenopausal women with newly diagnosed breast cancer. Eur. J. Clin. Nutr., 2002, 56(9), 925-927.
312. Paumgartner, G.; Beuers, U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology, 2002, 36(3), 525-531.
313. Perez, M. J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol., 2009, 15(14), 1677-1689.
314. Wang, H. H.; Portincasa, P.; De Bari, O.; Liu, K. J.; Garruti, G.; Neuschwander-Tetri, B. A.; Wang, D. Q. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur. J. Clin. Invest., 2013, 43(4), 413-426.
315. Olausson, M.; Mjornstedt, L.; Wramner, L.; Persson, H.; Karlberg, I.; Friman, S. Adjuvant treatment with ursodeoxycholic acid prevents acute rejection in rats receiving heart allografts. Transpl. Int., 1992, 5(Suppl 1), S539-S541.
316. Giordano, C.; Rivas, J.; Zervos, X. An update on treatment of drug-induced liver injury. J. Clin. Transl. Hepatol., 2014, 2(2), 74-79.
317. Ricci, P.; Hofmann, A. F.; Hagey, L. R.; Jorgensen, R. A.; Rolland Dickson, E.; Lindor, K. D. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig. Dis. Sci., 1998, 43(6), 1292-1295.
318. Medina, J. F.; Martinez, A.; Vazquez, J. J.; Prieto, J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology, 1997, 25(1), 12-17.
319. +exchanger activities in primary biliary cirrhosis. Hepatology, 2002, 35(6), 1513-1521.
320. Olsson, R.; Boberg, K. M.; De Muckadell, O. S.; Lindgren, S.; Hultcrantz, R.; Folvik, G.; Bell, H.; Gangsoy-Kristiansen, M.; Matre, J.; Rydning, A.; Wikman, O.; Danielsson, A.; Sandberg-Gertzen, H.; Ung, K. A.; Eriksson, A.; Loof, L.; Prytz, H.; Marschall, H. U.; Broome, U. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology, 2005, 129(5), 1464-1472.
321. Imam, M. H.; Sinakos, E.; Gossard, A. A.; Kowdley, K. V.; Luketic, V. A.; Edwyn Harrison, M.; McCashland, T.; Befeler, A. S.; Harnois, D.; Jorgensen, R.; Petz, J.; Keach, J.; DeCook, A. C.; Enders, F.; Lindor, K. D. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment. Pharmacol. Ther., 2011, 34(10), 1185-1192.
322. Wunsch, E.; Trottier, J.; Milkiewicz, M.; Raszeja-Wyszomirska, J.; Hirschfield, G. M.; Barbier, O.; Milkiewicz, P. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology, 2014, 60(3), 931-940.
323. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6a-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45(17), 3569-3572.
324. Kullak-Ublick, G. A.; Glasa, J.; Boker, C; Oswald, M.; Grutzner, U.; Hagenbuch, B.; Stieger, B.; Meier, P. J.; Beuers, U.; Kramer, W.; Wess, G.; Paumgartner, G. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology, 1997, 113(4), 1295-1305.
325. Im, E. O.; Choi, Y. H.; Paik, K. J.; Suh, H.; Jin, Y.; Kim, K. W.; Yoo, Y. H.; Kim, N. D. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett., 2001, 163(1), 83-93.
326. Carrasco, J.; Criado, J. J.; Macias, R. I.; Manzano, J. L.; Marin, J. J.; Medarde, M.; Rodriguez, E. Structural characterization and cytostatic activity of chlorobischolylglycinatogold (III). J. Inorg. Biochem., 2001, 84(3-4), 287-292.
327. Criado, J. J.; Macias, R. I.; Medarde, M.; Monte, M. J.; Serrano, M. A.; Marin, J. J. Synthesis and characterization of the new cytostatic complex cis-diammineplatinum (II)-chlorocholylglycinate. Bioconjug. Chem., 1997, 8(4), 453-458.
328. Criado, J. J.; Dominguez, M. F.; Medarde, M.; Fernandez, E. R.; Macias, R. I.; Marin, J. J. Structural characterization, kinetic studies, and In vitro biological activity of new cis-diamminebis-cholylglycinate (O, O') Pt (II) and cis-diamminebis-ursodeoxycholate (O, O') Pt (II) complexes. Bioconjug. Chem., 2000, 11(2), 167-174.
329. Briz, O.; Serrano, M. A.; Rebollo, N.; Hagenbuch, B.; Meier, P. J.; Koepsell, H.; Marin, J. J. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum (II) and cis-diammine-bisursodeoxycholate-platinum (II) toward liver cells. Mol. Pharmacol, 2002, 61(4), 853-860.
330. Marin, J. J.; Palomero, M. F.; Herrera, M. C.; Macias, R. I.; Criado, J. J.; Serrano, M. A. In vitro cytostatic activity and DNA-interaction of the new liver organotropic complex chloro-bis-cholylglycinate-platinum (II). Anticancer Res., 1998, 18(3A), 1641-1647.
331. Monte, M. J.; Dominguez, S.; Palomero, M. F.; Macias, R. I.; Marin, J. J. Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. J. Hepatol, 1999, 31(3), 521-528.
332. Lozano, E.; Monte, M. J.; Briz, O.; Hernandez-Hernandez, A.; Banales, J. M.; Marin, J. J.; Macias, R. I. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). J. Control. Release, 2015, 216, 93-102.
333. Dominguez, M. F.; Macias, R. I.; Izco-Basurko, I.; De La Fuente, A.; Pascual, M. J.; Criado, J. M.; Monte, M. J.; Yajeya, J.; Marin, J. J. Low In vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther., 2001, 297(3), 1106-1112.
334. Briz, O.; Serrano, M. A.; Macias, R. I.; Marin, J. J. Overcoming cisplatin resistance In vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. Int. J. Cancer, 2000, 88(2), 287-292.
335. Paschke, R.; Kalbitz, J.; Paetz, C; Luckner, M.; Mueller, T.; Schmoll, H. J.; Mueller, H.; Sorkau, E.; Sinn, E. Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J. Inorg. Biochem., 2003, 94(4), 335-342.
336. Hamman, J. H.; Enslin, G. M.; Kotze, A. F. Oral delivery of peptide drugs: barriers and developments. BioDrugs, 2005, 19(3), 165-177.
337. Kramer, W.; Wess, G.; Neckermann, G.; Schubert, G.; Fink, J.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K. H.; Boger, G.; et al., Enhsen, A.; Falk, E.; Friedrich, M.; Glombik, H.; Hoffmann, A.; Pittius, C; Urman, M. Intestinal absorption of peptides by coupling to bile acids. J. Biol. Chem., 1994, 269(14), 10621-10627.
338. Petzinger, E.; Wickboldt, A.; Pagels, P.; Starke, D.; Kramer, W. Hepatobiliary transport of bile acid amino acid, bile acid peptide, and bile acid oligonucleotide conjugates in rats. Hepatology, 1999, 30(5), 1257-1268.
339. Kim, S. K.; Lee, D. Y.; Kim, C. Y.; Nam, J. H.; Moon, H. T.; Byun, Y. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. J. Control. Release, 2007, 123(2), 155-163.
340. Alam, F.; Al-Hilal, T. A.; Chung, S. W.; Seo, D.; Mahmud, F.; Kim, H. S.; Kim, S. Y.; Byun, Y. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials, 2014, 35(24), 6543-6552.
341. Gonzalez-Carmona, M. A.; Quasdorff, M.; Vogt, A.; Tamke, A.; Yildiz, Y.; Hoffmann, P.; Lehmann, T.; Bartenschlager, R.; Engels, J. W.; Kullak-Ublick, G. A.; Sauerbruch, T.; Caselmann, W. H. Inhibition of hepatitis C virus RNA translation by antisense bile acid conjugated phosphorothioate modified oligodeoxynucleotides (ODN). Antiviral Res., 2013, 97(1), 49-59.
342. Lischka, K.; Starke, D.; Failing, K.; Herling, A.; Kramer, W.; Petzinger, E. Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in Wistar and TR-rats: evidence for mrp2 as carrier for oligodeoxynucleotides. Biochem. Pharmacol, 2003, 66(4), 565-577.
343. Niedzinski, E. J.; Bennett, M. J.; Olson, D. C.; Nantz, M. H. Gastroprotection of DNA with a synthetic cholic acid analog. Lipids, 2000, 35(7), 721-727.
344. Whittingham, J. L.; Jonassen, I.; Havelund, S.; Roberts, S. M.; Dodson, E. J.; Verma, C. S.; Wilkinson, A. J.; Dodson, G. G. Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins. Biochemistry, 2004, 43(20), 5987-5995.
345. Park, J. H.; Kwon, S.; Nam, J. O.; Park, R. W.; Chung, H.; Seo, S. B.; Kim, I. S.; Kwon, I. C.; Jeong, S. Y. Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery. J. Control. Release, 2004, 95(3), 579-588.
346. Valenta, C; Nowack, E.; Bernkop-Schnurch, A. Deoxycholate-hydrogels: novel drug carrier systems for topical use. Int. J. Pharm., 1999, 185(1), 103-111.
347. Fricker, G.; Fahr, A.; Beglinger, C; Kissel, T.; Reiter, G.; Drewe, J. Permeation enhancement of octreotide by specific bile salts in rats and human subjects: In vitro, In vivo correlations. Br. J. Pharmacol, 1996, 117(1), 217-223.
348. Michael, S.; Thole, M.; Dillmann, R.; Fahr, A.; Drewe, J.; Fricker, G. Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur. J. Pharm. Sci., 2000, 10(2), 133-140.
349. Schneider, S. M.; Joly, F.; Gehrardt, M. F.; Badran, A. M.; Myara, A.; Thuillier, F.; Coudray-Lucas, C; Cynober, L.; Trivin, F.; Messing, B. Taurine status and response to intravenous taurine supplementation in adults with short-bowel syndrome undergoing long-term parenteral nutrition: a pilot study. Br. J. Nutr., 2006, 96(2), 365-370.
350. Mikov, M.; Kevresan, S.; Kuhajda, K.; Jakovljevic, V.; Vasovic, V. 3α, 7α-dihydroxy-12-oxo-5β-cholanate as blood-brain barrier permeator. Pol. J. Pharmacol, 2004, 56(3), 367-371.
351. -/-mice. Atherosclerosis 2013, 229(2), 374-380.
352. Chen, L.; Yao, X.; Young, A.; McNulty, J.; Anderson, D.; Liu, Y.; Nystrom, C.; Croom, D.; Ross, S.; Collins, J.; Rajpal, D.; Hamlet, K.; Smith, C.; Gedulin, B. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am. J. Physiol. Endocrinol. Metab., 2012, 302(1), E68-E76.
353. Zheng, X.; Ekins, S.; Raufman, J. P.; Polli, J. E. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol. Pharm., 2009, 6(5), 1591-1603.
354. +/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters. Life Sci., 1997, 60(24), PL 365-370.
355. Dawson, P. A. Impact of inhibiting ileal apical versus basolateral bile acid transport on cholesterol metabolism and atherosclerosis in mice. Dig. Dis., 2015, 33(3), 382-387.
356. Kramer, W.; Glombik, H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem., 2006, 13(9), 997-1016.
357. Vicens, M.; Medarde, M.; Macias, R. I.; Larena, M. G.; Villafaina, A.; Serrano, M. A.; Marin, J. J. Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorg. Med. Chem., 2007, 15(6), 2359-2367.
358. Vicens, M.; Macias, R. I.; Briz, O.; Rodriguez, A.; El-Mir, M. Y.; Medarde, M.; Marin, J. J. Inhibition of the intestinal absorption of bile acids using cationic derivatives: mechanism and repercussions. Biochem. Pharmacol., 2007, 73(3), 394-404.
359. Park, J.; Al-Hilal, T. A.; Jeong, J. H.; Choi, J. U.; Byun, Y. Design, synthesis, and therapeutic evaluation of poly (acrylic acid)-tetraDOCA conjugate as a bile acid transporter inhibitor. Bioconjug. Chem., 2015, 26(8), 1597-1605.
360. Fehrenbach, T.; Cui, Y.; Faulstich, H.; Keppler, D. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn-Schmiedeberg's Arch. Pharmacol., 2003, 368(5), 415-420.
361. Letschert, K.; Faulstich, H.; Keller, D.; Keppler, D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 2006, 91(1), 140-149.
362. Herraez, E.; Macias, R. I.; Vazquez-Tato, J.; Vicens, M.; Monte, M. J.; Marin, J. J. In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicol. Appl. Pharmacol., 2009, 239(1), 13-20.
363. Herraez, E.; Macias, R. I.; Vazquez-Tato, J.; Hierro, C.; Monte, M. J.; Marin, J. J. Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicol. Appl. Pharmacol., 2009, 239(1), 21-28.
364. Schmidt, E. J.; Boswell, J. S.; Walsh, J. P.; Schellenberg, M. M.; Winter, T. W.; Li, C; Allman, G. W.; Savage, P. B., Activities of cholic acid-derived antimicrobial agents against multidrug-resistant bacteria. J. Antimicrob. Chemother., 2001, 47(5), 671-674.
365. Lorenzo-Zuniga, V.; Bartoli, R.; Planas, R.; Hofmann, A. F.; Vinado, B.; Hagey, L. R.; Hernandez, J. M.; Mane, J.; Alvarez, M. A.; Ausina, V.; Gassull, M. A. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology, 2003, 37(3), 551-557.
366. Troisi, G.; Crisciotti, F.; Gianturco, V.; D'Ottavio, E.; Lo Iacono, C; Formosa, V.; Bernardini, S.; Bellomo, A.; Marigliano, B.; Marigliano, V. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. Clin. Ter., 2013, 164(3), 203-207.
367. Floreani, A.; Cazzagon, N.; Franceschet, I.; Canesso, F.; Salmaso, L.; Baldo, V. Metabolic syndrome associated with primary biliary cirrhosis. J. Clin. Gastroenterol, 2015, 49(1), 57-60.
368. Adachi, R.; Honma, Y.; Masuno, H.; Kawana, K.; Shimomura, I.; Yamada, S.; Makishima, M. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res., 2005, 46(1), 46-57.
369. Song, C; Hiipakka, R. A.; Liao, S., Selective activation of liver X receptora by 6α-hydroxy bile acids and analogs. Steroids, 2000, 65(8), 423-427.
370. Marin, J. J., Plasma membrane transporters in modern liver pharmacology. Scientifica (Cairo), 2012, 2012, 428139.
371. Marin, J. J.; Briz, O.; Perez, M. J.; Romero, M. R.; Monte, M. J. Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs. Front. Biosci. (Landmark Ed), 2009, 14, 4257-4280.
372. Sakamoto, S.; Kusuhara, H.; Miyata, K.; Shimaoka, H.; Kanazu, T.; Matsuo, Y.; Nomura, K.; Okamura, N.; Hara, S.; Horie, K.; Baba, T.; Sugiyama, Y. Glucuronidation converting methyl 1-(3, 4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6, 7, 8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther., 2007, 322(2), 610-618.
373. Yan, H.; Li, W. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and d virus. Dig. Dis., 2015, 33(3), 388-396.
374. Meng, Q.; Chen, X.; Wang, C; Liu, Q.; Sun, H.; Sun, P.; Peng, J.; Liu, K. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem. Pharmacol, 2014, 92(2), 289-298.
375. Meng, Q.; Chen, X. L.; Wang, C. Y.; Liu, Q.; Sun, H. J.; Sun, P. Y.; Huo, X. K.; Liu, Z. H.; Yao, J. H.; Liu, K. X. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis. Toxicol. Appl. Pharmacol, 2015, 283(3), 178-186.